Patient Square Capital’s Xenon Pharmaceuticals XENE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-220,000
Closed -$13.3M – 29
2026
Q2
$13.3M Sell
220,000
-7,000
-3% -$389K 2.06% 12
2026
Q1
$13.2M Buy
227,000
+90,500
+66% +$4.17M 2.34% 13
2025
Q4
$6.12M Buy
+136,500
New +$5.73M 1.31% 17

Other funds holding XENE

Patient Square Capital's XENE Position: Q3 2026 in Review

Patient Square Capital sold out of Xenon Pharmaceuticals (XENE) in Q3 2026, closing a stake of 220,000 shares — an estimated $13.3M sold.

Patient Square Capital first reported a position in XENE in Q4 2025 and held it in 3 quarters. The position peaked at $13.3M in Q2 2026. 286 funds tracked by Wall St. Rank hold XENE as of Q3 2026.

  • Patient Square Capital reported no remaining Xenon Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Patient Square Capital sold 220,000 Xenon Pharmaceuticals shares in Q3 2026, an estimated $13.3M.
  • Patient Square Capital first reported a position in Xenon Pharmaceuticals in Q4 2025 and held it in 3 quarters.
  • Patient Square Capital's Xenon Pharmaceuticals position peaked at $13.3M in Q2 2026.
  • 286 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2026.

Based on Patient Square Capital's 13F filing for Q3 2026, filed 10 Nov 2026.